March 23, 2020 / 2:10 PM / 2 months ago

BRIEF-Genentech - Phase III Viale-A Study Met Its Dual Primary Endpoints Of Overall Survival And Composite Complete Remission Rate

March 23 (Reuters) - Genentech:

* GENENTECH - PHASE III VIALE-A STUDY MET ITS DUAL PRIMARY ENDPOINTS OF OVERALL SURVIVAL AND COMPOSITE COMPLETE REMISSION RATE

* GENENTECH - SAFETY FOR VENCLEXTA PLUS AZACITIDINE APPEARED CONSISTENT WITH KNOWN SAFETY PROFILE OF THESE MEDICINES

* GENENTECH - VENCLEXTA IS BEING DEVELOPED BY ABBVIE AND GENENTECH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below